You are here

Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-18-C-0031
Agency Tracking Number: C2-0482
Amount: $994,237.59
Phase: Phase II
Program: STTR
Solicitation Topic Code: CBD15C-001
Solicitation Number: 2015.0
Timeline
Solicitation Year: 2015
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-03-16
Award End Date (Contract End Date): 2020-03-15
Small Business Information
601 Genome Way, Huntsville, AL, 35806
DUNS: 964433838
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Paula Koelle
 (256) 679-8660
 pkoelle@genecapture.com
Business Contact
 Peggy Sammon
Phone: (256) 783-4506
Email: psammon@genecapture.com
Research Institution
 Southern Research
 Catherine Bigger, Ph.D.
 2000 Ninth Avenue South
Birmingham, AL, 35205
 (205) 581-2142
 Domestic nonprofit research organization
Abstract
GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we plan tocontinue our device maturation by integrating automated sample preparation into the disposable cartridge, modifying the fluid path foroptimal target acquisition, expanding the Febrile Illness panel and progressing the commercialization of the product. The goal of this Topic is aportable pathogen detection system for undifferentiated febrile illnesses for use in far-forward environments by the Warfighter. Thepathogens of interest for this Phase II effort include Influenza, Dengue, Chikungunya, Lassa Fever, and Crimean-Congo Hemorrhagic Feverviruses, and the bacteria Yersinia pestis, Rickettsia typhi, Francisella tularensis and Burkholderia species. The assay will also differentiatesamples containing bacterial agents from those containing fungal or viral pathogens.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government